Mast cells in abdominal aortic aneurysms

Current Vascular Pharmacology

Volumn 11, Issue 3, 2013, Pages 314-326

  Shi, Guo Ping ^a   Lindholt, Jes S ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Abdominal aortic aneurysm; Angiogenesis; Apoptosis; Chymase; Extracellular matrix protein; Inflammation; Mast cell; Tryptase

Indexed keywords

ANAPHYLATOXIN; BATIMASTAT; CASPASE 8; CASPASE 9; CROMOGLYCATE DISODIUM; CXCL2 CHEMOKINE; DIPEPTIDYL PEPTIDASE I; DOXYCYCLINE; GAMMA INTERFERON; GELATINASE B; GLUCOCORTICOID; INTERLEUKIN 6; KETOTIFEN; N [1 BENZYL 2, 3 DIOXO 6 (2 PYRIDYLOXY) HEXYL] 2 (5 FORMYLAMINO 1, 6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL) ACETAMIDE; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; NEUTROPHIL COLLAGENASE; PEMIROLAST; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANILAST; TRYPTASE; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ANGIOGENESIS; APOPTOSIS; ARTERY LESION; ARTICLE; ATHEROSCLEROSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; INFLAMMATORY CELL; MAST CELL; MAST CELL DEGRANULATION; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; CHYMASES; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MAST CELLS; MOLECULAR TARGETED THERAPY; TRYPTASES;

EID: 84878626298     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311030006     Document Type: Article

References (142)

1. Ihara M, Urata H, Kinoshita A, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999; 33: 1399-405.
2. Swedenborg J, Mäyränpää MI, Kovanen PT. Mast cells: important players in the orchestrated pathogenesis of abdominal aortic aneu-rysms. Arterioscler Thromb Vasc Biol 2011; 31: 734-40.
3. Sun J, Sukhova GK, Yang M, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest 2007; 117: 3359-68.
4. Xu J, Shi GP. Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev 2011; 33: 71-108.
5. Kazi M, Thyberg J, Religa P, et al. Influence of intraluminal thrombus on structural and cellular composition of abdominal aortic aneurysm wall. J Vasc Surg 2003; 38: 1283-92.
6. Stenbaek J, Kalin B, Swedenborg J. Growth of thrombus may be a better predictor of rupture than diameter in patients with abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2000; 20: 466-9.
7. Simão da Silva E, Rodrigues AJ, Magalhães Castro de Tolosa E, Rodrigues CJ, Villas Boas do Prado G, Nakamoto JC. Morphology and diameter of infrarenal aortic aneurysms: a prospective autopsy study. Cardiovasc Surg 2000; 8: 526-32.
8. Eliason JL, Hannawa KK, Ailawadi G, et al. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. Circulation 2005; 112: 232-40.
9. MacSweeney ST, Powell JT, Greenhalgh RM. Pathogenesis of abdominal aortic aneurysm. Br J Surg 1994; 81: 935-41.
10. Hans SS, Jareunpoon O, Balasubramaniam M, Zelenock GB. Size and location of thrombus in intact and ruptured abdominal aortic aneurysms. J Vasc Surg 2005; 41: 584-8.
11. Fontaine V, Jacob MP, Houard X, et al. Involvement of the mural thrombus as a site of protease release and activation in human aor tic aneurysms. Am J Pathol 2002; 161: 1701-10.
12. Choke E, Thompson MM, Dawson J, et al. Abdominal aortic aneu-rysm rupture is associated with increased medial neovasculariza-tion and overexpression of proangiogenic cytokines. Arterioscler Thromb Vasc Biol 2006; 26: 2077-82.
13. Halme S, Juvonen T, Laurila A, et al. Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms. Eur J Clin Invest 1999; 29: 546-52.
14. Reeps C, Pelisek J, Seidl S, et al. Inflammatory infiltrates and neovessels are relevant sources of MMPs in abdominal aortic aneu-rysm wall. Pathobiology 2009; 76: 243-52.
15. Forester ND, Cruickshank SM, Scott DJ, Carding SR. Functional characterization of T cells in abdominal aortic aneurysms. Immunology 2005; 115: 262-70.
16. Zhang J, Böckler D, Ryschich E, et al. Impaired Fas-induced apop-tosis of T lymphocytes in patients with abdominal aortic aneu-rysms. J Vasc Surg 2007; 45: 1039-46.
17. Galle C, Schandené L, Stordeur P, et al. Predominance of type 1 CD4+ T cells in human abdominal aortic aneurysm. Clin Exp Immunol 2005; 142: 519-27.
18. Schönbeck U, Sukhova GK, Gerdes N, Libby P. T(H)2 predominant immune responses prevail in human abdominal aortic aneu-rysm. Am J Pathol 2002; 161: 499-506.
19. Szekanecz Z, Shah MR, Pearce WH, Koch AE. Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and in-terferon-gamma but not IL-2 and IL-4: the possible role for IL-6 and interferon-gamma in vascular inflammation. Agents Actions 1994; 42: 159-62.
20. Juvonen J, Surcel HM, Satta J, et al. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneu-rysm. Arterioscler Thromb Vasc Biol 1997; 17: 2843-7.
21. Xiong W, Zhao Y, Prall A, Baxter BT. Key roles of CD4+ T cells and IFN-gamma in the development of abdominal aortic aneurysms in a murine model. J Immunol 2004; 172: 2607-12.
22. Xiong W, MacTaggart J, Knispel R, Baxter BT. Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol 2009; 183: 2741-6.
23. King VL, Lin AY, Kristo F, et al. Interferon-gamma and the inter-feron-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation 2009; 119: 426-35.
24. Shimizu K, Shichiri M, Libby P, Lee RT, Mitchell RN. Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest 204; 114: 300-8.
25. Mäyränpää MI, Trosien JA, Fontaine V, et al. Mast cells associate with neovessels in the media and adventitia of abdominal aortic an-eurysms. J Vasc Surg 2009; 50: 388-95.
26. Sakamoto S, Tsuruda T, Hatakeyama K, et al. Mast cell density and distribution in human abdominal aortic aneurysm. In: Grund-mann R, Ed. Mast cell density and distribution in human abdominal aortic aneurysm. InTech: 2011; pp. 55-66.
27. Tsunemi K, Takai S, Nishimoto M, et al. Possible roles of angio-tensin II-forming enzymes, angiotensin converting enzyme and chymase-like enzyme, in the human aneurysmal aorta. Hypertens Res 2002; 25: 817-22.
28. Tsuruda T, Kato J, Hatakeyama K, et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 2008; 102: 1368-77.
29. Mierke CT, Ballmaier M, Werner U, Manns MP, Welte K, Bischoff SC. Human endothelial cells regulate survival and proliferation of human mast cells. J Exp Med 2000; 192: 801-11.
30. Heikkilä HM, Lätti S, Leskinen MJ, Hakala JK, Kovanen PT, Lindstedt KA. Activated mast cells induce endothelial cell apopto-sis by a combined action of chymase and tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol 2008; 28: 309-14.
31. Kovanen PT. Mast cells in atherogenesis: actions and reactions. Curr Atheroscler Rep 2009; 11: 214-9.
32. Donelan J, Boucher W, Papadopoulou N, et al. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 2006; 103: 7759-64.
33. von Stebut E, Metz M, Milon G, Knop J, Maurer M. Early macro-phage influx to sites of cutaneous granuloma formation is dependent on MIP-1alpha /beta released from neutrophils recruited by mast cell-derived TNF alpha. Blood 2003; 101: 210-5.
34. Stelekati E, Orinska Z, Bulfone-Paus S. Mast cells in allergy: innate instructors of adaptive responses. Immunobiology 2007; 212: 505-19.
35. Strbian D, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ. Cerebral mast cells regulate early ischemic brain swelling and neu-trophil accumulation. J Cereb Blood Flow Metab 2006; 26: 605-12.
36. Tournilhac O, Santos DD, Xu L, et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 2006; 17: 1275-82.
37. Mazzoni A, Siraganian RP, Leifer CA, Segal DM. Dendritic cell modulation by mast cells controls the Th1/Th2 balance in responding T cells. J Immunol 2006; 177: 3577-81.
38. Lindstedt KA, Mäyränpää MI, Kovanen PT. Mast cells in vulnerable atherosclerotic plaques-a view to a kill. J Cell Mol Med 2007; 11: 739-58.
39. Nishida M, Uchikawa R, Tegoshi T, et al. Migration of neutrophils is dependent on mast cells in non-specific pleurisy in rats. APMIS 1999; 107: 929-36.
40. Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA. Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J Immunol 2001; 167: 4008-16.
41. Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cells enhance T cell activation: Importance of mast cell-derived TNF. Proc Natl Acad Sci USA 2005; 102: 6467-72.
42. Wei YF, Heghinian K, Bell RL, Jakschik BA. Contribution of macrophages to immediate hypersensitivity reaction. J Immunol 1986; 137: 1993-2000.
43. Stelekati E, Bahri R, D'Orlando O, et al. Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity 2009; 31: 665-76.
44. Dobrin PB, Mrkvicka R. Failure of elastin or collagen as possible critical connective tissue alterations underlying aneurysmal dilatation. Cardiovasc Surg 1994; 2: 484-8.
45. Dobrin PB, Baker WH, Gley WC. Elastolytic and collagenolytic studies of arteries. Implications for the mechanical properties of aneurysms. Arch Surg 1984; 119: 405-9.
46. Isenburg JC, Simionescu DT, Starcher BC, Starcher BC, Vyava-hare NR. Elastin stabilization for treatment of abdominal aortic an-eurysms. Circulation 2007; 115: 1729-37.
47. Ma Mäki JM, Räsänen J, Tikkanen H, et al. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation 2002; 106: 2503-9.
48. Rowe DW, McGoodwin EB, Martin GR, Grahn D. Decreased lysyl oxidase activity in the aneurysm-prone, mottled mouse. J Biol Chem 1977; 252: 939-42.
49. Yoshimura K, Aoki H, Ikeda Y, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 2005; 11: 1330-8.
50. Huffman MD, Curci JA, Moore G, Kerns DB, Starcher BC, Thompson RW. Functional importance of connective tissue repair during the development of experimental abdominal aortic aneu-rysms. Surgery 2000; 128: 429-38.
51. Ha VT, Marshall MK, Elsas LJ, Pinnell SR, Yeowell HN. A patient with Ehlers-Danlos syndrome type VI is a compound heterozygote for mutations in the lysyl hydroxylase gene. J Clin Invest 1994; 93: 1716-21.
52. Allaire E, Muscatelli-Groux B, Guinault AM, et al. Vascular smooth muscle cell endovascular therapy stabilizes already developed aneurysms in a model of aortic injury elicited by inflammation and proteolysis. Ann Surg 2004; 239: 417-27.
53. Dai J, Losy F, Guinault AM, et al. Overexpression of transforming growth factor-beta1 stabilizes already-formed aortic aneurysms: a first approach to induction of functional healing by endovascular gene therapy. Circulation 2005; 112: 1008-15.
54. Deguchi JO, Huang H, Libby P, et al. Genetically engineered resistance for MMP collagenases promotes abdominal aortic aneurysm formation in mice infused with angiotensin II. Lab Invest 2009; 89: 315-26.
55. Sun J, Sukhova GK, Wolters PJ, et al. Mast cells promote atherosclerosis by releasing pro-inflammatory cytokines. Nat Med 2007; 13: 719-24.
56. Tsuruda T, Kato J, Hatakeyama K, et al. Adrenomedullin in mast cells of abdominal aortic aneurysm. Cardiovasc Res 2006; 70: 158-64.
57. Tsuruda T, Kato J, Cao YN, et al. Adrenomedullin induces matrix metalloproteinase-2 activity in rat aortic adventitial fibroblasts. Biochem Biophys Res Commun 2004; 325: 80-4.
58. Tsuruda T, Kato J, Hatakeyama K, et al. Antifibrotic effect of adrenomedullin on coronary adventitia in angiotensin II-induced hypertensive rats. Cardiovasc Res 2005; 65: 921-9.
59. Pejler G, Abrink M, Ringvall M, Wernersson S. Mast cell proteases. Adv Immunol 2007; 95: 167-255.
60. Kimata M, Ishizaki M, Tanaka H, Nagai H, Inagaki N. Production of matrix metalloproteinases in human cultured mast cells: involvement of protein kinase C-mitogen activated protein kinase kinase-extracellular signal-regulated kinase pathway. Allergol Int 2006; 55: 67-76.
61. Edwards ST, Cruz AC, Donnelly S, et al. c-Kit immunophenotyp-ing and metalloproteinase expression profiles of mast cells in interstitial lung diseases. J Pathol 2005; 206: 279-90.
62. Mallen-St Clair J, Shi GP, Sutherland RE, Chapman HA, Caughey GH, Wolters PJ. Cathepsins L and S are not required for activation of dipeptidyl peptidase I (cathepsin C) in mice. Biol Chem 2006; 387: 1143-6.
63. Sereda MJ, Bradding P, Vial C. Adenosine potentiates human lung mast cell tissue plasminogen activator activity. J Immunol 2011; 186: 1209-17.
64. Ribatti D, Nico B, Finato N, Crivellato E, Beltrami CA.Co-localization of tryptase and cathepsin-G in mast cells in cutaneous mastocytosis. Cancer Lett 2009; 279: 209-12.
65. Strik MC, de Koning PJ, Kleijmeer MJ, et al. Human mast cells produce and release the cytotoxic lymphocyte associated protease granzyme B upon activation. Mol Immunol 2007; 44: 3462-72.
66. Wilson WR, Choke EC, Dawson J, Loftus IM, Thompson MM. Plasma matrix metalloproteinase levels do not predict tissue levels in abdominal aortic aneurysms suitable for elective repair. Vascular 2008; 16: 248-52.
67. Karlsson L, Bergqvist D, Lindbäck J, Pärsson H. Expansion of small-diameter abdominal aortic aneurysms is not reflected by the release of inflammatory mediators IL-6, MMP-9 and CRP in plasma. Eur J Vasc Endovasc Surg 2009; 37: 420-4.
68. Wilson WR, Anderton M, Choke EC, Dawson J, Loftus IM, Thompson MM. Elevated plasma MMP1 and MMP9 are associated with abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg 2008; 35: 580-4.
69. Lindholt JS, Vammen S, Fasting H, Henneberg EW, Heickendorff L. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study. Eur J Vasc Endovasc Surg 2000; 20: 281-5.
70. Wilson WR, Anderton M, Schwalbe EC, et al. Matrix metallopro-teinase-8 and-9 are increased at the site of abdominal aortic aneu-rysm rupture. Circulation 2006; 113: 438-45.
71. Wiernicki I, Stachowska E, Safranow K, et al. Enhanced matrix-degrading proteolytic activity within the thin thrombus-covered wall of human abdominal aortic aneurysms. Atherosclerosis 2010; 212: 161-5.
72. Gruber BL, Marchese MJ, Suzuki K, et al. Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J Clin Invest 1989; 84: 1657-62.
73. Saarinen J, Kalkkinen N, Welgus HG, Kovanen PT. Activation of human interstitial procollagenase through direct cleavage of the Leu83-Thr84 bond by mast cell chymase. J Biol Chem 1994; 269: 18134-40.
74. Okada Y, Nakanishi I. Activation of matrix metalloproteinase 3 (stromelysin) and matrix metalloproteinase 2 ('gelatinase') by human neutrophil elastase and cathepsin G. FEBS Lett 1989; 249: 353-6.
75. Saunders WB, Bayless KJ, Davis GE. MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J Cell Sci 2005; 118: 2325-40.
76. Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110: 625-32.
77. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000; 105: 1641-9.
78. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elas-tase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD ge-latinase. J Vasc Surg 1996; 23: 336-46.
79. Miralles M, Wester W, Sicard GA, Thompson R, Reilly JM. Indo-methacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. J Vasc Surg 1999; 29: 884-92.
80. Armstrong PJ, Franklin DP, Carey DJ, Elmore JR http://www.ncbi. nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed?term=%22Swedenborg J%22%5BAuthor%5D. Suppression of experimental aortic aneu-rysms: comparison of inducible nitric oxide synthase and cy-clooxygenase inhibitors. Ann Vasc Surg 2005; 19: 248-57.
81. Shi G-P, Sukhova GK, Grubb A, et al. Cystatin C deficiency inhuman atherosclerosis and aortic aneurysms. J Clin Invest 1999; 104: 1191-7.
82. Abisi S, Burnand KG, Waltham M, Humphries J, Taylor PR, Smith A. Cysteine protease activity in the wall of abdominal aortic aneu-rysms. J Vasc Surg 2007; 46: 1260-6.
83. Abdul-Hussien H, Soekhoe RG, Weber E, et al. Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metallopro-teinase and cysteine collagenases. Am J Pathol 2007; 170: 809-17.
84. Pagano MB, Bartoli MA, Ennis TL, et al. Critical role of dipeptidyl peptidase I in neutrophil recruitment during the development of experimental abdominal aortic aneurysms. Proc Natl Acad Sci USA 2007; 104: 2855-60.
85. Takai S, Jin D, Miyazaki M. New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage. J Pharmacol Sci 2010; 113: 301-9.
86. Sun J, Sukhova GK, Zhang J, et al. Cathepsin K deficiency reduces elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol 2012; 32:15-23.
87. Sun J, Sukhova GK, Zhang J, et al. Cathepsin L activity is essential to elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol 2011; 31: 2500-8.
88. Chapman HA, Riese RJ, Shi G-P. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997; 59: 63-88.
89. Shi G-P, Sukhova GK, Kuzuya M, et al. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res 2003; 92: 493-500.
90. Wanhainen A, Nilsson TK, Bergqvist D, Boman K, Björck M. Elevated tissue plasminogen activator in patients with screening-detected abdominal aortic aneurysm. J Vasc Surg 2007; 45: 1109-13.
91. Lindholt JS. Activators of plasminogen and the progression of small abdominal aortic aneurysms. Ann N Y Acad Sci 2006; 1085: 139-50.
92. Qian HS, Gu JM, Liu P, et al. Overexpression of PAI-1 prevents the development of abdominal aortic aneurysm in mice. Gene Ther 2008; 15: 224-32.
93. Chamberlain CM, Ang LS, Boivin WA, et al. Perforin-independent extracellular granzyme B activity contributes to abdominal aortic aneurysm. Am J Pathol 2010; 176: 1038-49.
94. Kaschina E, Scholz H, Steckelings UM, et al. Transition from atherosclerosis to aortic aneurysm in humans coincides with an increased expression of RAS components. Atherosclerosis 2009; 205: 396-403.
95. Miyazaki M, Takai S, Jin D, Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther 2006; 112: 668-76.
96. Owen CA, Campbell EJ. Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. J Immunol 1998; 160: 1436-43.
97. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-8.
98. Fang KC, Raymond WW, Blount JL, Caughey GH. Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe88-Gln89 and Phe91-Glu92 bonds of the catalytic domain. J Biol Chem 1997; 272: 25628-35.
99. Nishimoto M, Takai S, Fukumoto H, et al. Increased local angio-tensin II formation in aneurysmal aorta. Life Sci 2002; 71: 2195-205.
100. Furubayashi K, Takai S, Jin D, et al. Chymase activates promatrix metalloproteinase-9 in human abdominal aortic aneurysm. Clin Chim Acta 2008; 388: 214-6.
101. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005; 280: 9291-6.
102. Leskinen M, Wang Y, Leszczynski D, Lindstedt KA, Kovanen PT. Mast cell chymase induces apoptosis of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21: 516-22.
103. Zhang J, Sun J, Lindholt JS, et al. Mast Cell Tryptase Deficiency Attenuates Mouse Abdominal Aortic Aneurysm Formation. Circ Res 2011; 108: 1316-27.
104. Sun J, Zhang J, Lindholt JS, et al. Critical role of mast cell chy-mase in mouse abdominal aortic aneurysm formation. Circulation 2009; 120: 973-82.
105. Kaartinen M, Penttilä A, Kovanen PT. Mast cells of two types differing in neutral protease composition in the human aortic in-tima. Demonstration of tryptase-and tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the shoulder region of atheromas. Arterioscler Thromb 1994; 14: 966-72.
106. Blair RJ, Meng H, Marchese MJ, et al. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997; 99: 2691-700.
107. Thompson MM, Jones L, Nasim A, Sayers RD, Bell PR. Angio-genesis in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1996; 11: 464-9.
108. Roy J, Labruto F, Beckman MO, Danielson J, Johansson G, Swe-denborg J. Bleeding into the intraluminal thrombus in abdominal aortic aneurysms is associated with rupture. J Vasc Surg 2008; 48: 1108-13.
109. Russo A, Russo G, Peticca M, Pietropaolo C, Di Rosa M, Iuvone T. Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5. Br J Pharmacol 2005; 145: 24-33.
110. Henderson EL, Geng YJ, Sukhova GK, Whittemore AD, Knox J, Libby P. Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneu-rysms. Circulation 1999; 99: 96-104.
111. Liao S, Curci JA, Kelley BJ, Sicard GA, Thompson RW. Accelerated replicative senescence of medial smooth muscle cells derived from abdominal aortic aneurysms compared to the adjacent inferior mesenteric artery. J Surg Res 2000; 92: 85-95.
112. Kovanen PT. Mast cells: multipotent local effector cells in atherothrombosis. Immunol Rev 2007; 217: 105-22.
113. Leskinen MJ, Heikkilä HM, Speer MY, et al. Mast cell chymase induces smooth muscle cell apoptosis by disrupting NF-kappaB-mediated survival signaling. Exp Cell Res 2006; 312: 1289-98.
114. Pardo J, Wallich R, Ebnet K, et al. Granzyme B is expressed in mouse mast cells in vivo and in vitro and causes delayed cell death independent of perforin. Cell Death Differ 2007; 14: 1768-79.
115. Wang Y, Shiota N, Leskinen MJ, Lindstedt KA, Kovanen PT. Mast cell chymase inhibits smooth muscle cell growth and collagen expression in vitro: transforming growth factor-beta1-dependent and-independent effects. Arterioscler Thromb Vasc Biol 2001; 21: 1928-33.
116. Paraskevas KI, Mikhailidis DP, Perrea D. Experimental models of abdominal aortic aneurysms: an overview. Curr Pharm Des 2008; 14: 325-37.
117. Gertz SD, Kurgan A, Eisenberg D. Aneurysm of the rabbit common carotid artery induced by periarterial application of calcium chloride in vivo. J Clin Invest 1988; 81: 649-56.
118. Anidjar S, Salzmann JL, Gentric D, Lagneau P, Camilleri JP, Michel JB. Elastase-induced experimental aneurysms in rats. Circulation 1990; 82: 973-81.
119. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105: 1605-12.
120. Tsujimura T, Hirota S, Nomura S, et al. Characterization of Ws mutant allele of rats: a 12-base deletion in tyrosine kinase domain of c-kit gene. Blood 1991; 78: 1942-6.
121. Komatsu H, Kojima M, Tsutsumi N, et al. Study of the mechanism of inhibitory action of tranilast on chemical mediator release. Jpn J Pharmacol 1988; 46: 43-51.
122. Fukuyama J, Ichikawa K, Hamano S, Shibata N. Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet. Eur J Pharmacol 1996; 318: 327-32.
123. Shimizu T, Kanai K, Kyo Y, Asano K, Hisamitsu T, Suzaki H. Effect of tranilast on matrix metalloproteinase production from neutrophils in-vitro. J Pharm Pharmacol 2006; 58: 91-9.
124. Olsson N, Piek E, Sundström M, ten Dijke P, Nilsson G. Transforming growth factor-beta-mediated mast cell migration depends on mitogen-activated protein kinase activity. Cell Signal 2001; 13: 483-90.
125. Ward MR, Sasahara T, Agrotis A, Dilley RJ, Jennings GL, Bobik A. Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries. Atherosclerosis 1998; 137: 267-75.
126. Haas PJ, van Strijp J. Anaphylatoxins: their role in bacterial infection and inflammation. Immunol Res 2007; 37: 161-75.
127. Hartmann K, Henz BM, Krüger-Krasagakes S, et al. C3a and C5a stimulate chemotaxis of human mast cells. Blood 1997; 89: 2863-70.
128. Kildsgaard J, Hollmann TJ, Matthews KW, Bian K, Murad F, Wetsel RA. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J Immunol 2000; 165: 5406-9.
129. Pagano MB, Zhou HF, Ennis TL, et al. Complement-dependent neutrophil recruitment is critical for the development of elastase-induced abdominal aortic aneurysm. Circulation 2009; 119: 1805-13.
130. Matsumoto M, Fukuda W, Circolo A, et al. Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc Natl Acad Sci USA 1997; 94: 8720-5.
131. Bigatel DA, Elmore JR, Carey DJ, Cizmeci-Smith G, Franklin DP, Youkey JR. The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. J Vasc Surg 1999; 29: 130-8.
132. Bartoli MA, Parodi FE, Chu J, et al. Localized administration of doxycycline suppresses aortic dilatation in an experimental mouse model of abdominal aortic aneurysm. Ann Vasc Surg 2006; 20: 228-36.
133. Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001; 34: 606-10.
134. Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg 2002; 36: 1-12.
135. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical trial of doxycycline for matrix metalloprote-inase-9 inhibition in patients with an abdominal aneurysm: doxycy-cline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 2009; 119: 2209-16.
136. Tsunemi K, Takai S, Nishimoto M, et al. A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[3,4-dioxo-1-phenyl-7-(2-pyridyloxy)]-2-heptyl]acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. J Pharmacol Exp Ther 2004; 309: 879-83.
137. Inoue N, Muramatsu M, Jin D, et al. Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. Atherosclerosis 2009; 204: 359-64.
138. Furubayashi K, Takai S, Jin D, et al. The significance of chymase in the progression of abdominal aortic aneurysms in dogs. Hyper-tens Res 2007; 30: 349-57.
139. Faleiro LC, Machado CR, Gripp A Jr, Resende RA, Rodrigues PA. Cerebral vasospasm: presence of mast cells in human cerebral arteries after aneurysm rupture. J Neurosurg 1981; 54: 733-5.
140. Ohsawa H, Noike H, Kanai M, et al. Preventive effect of an antiallergic drug, pemirolast potassium, on restenosis after stent placement: quantitative coronary angiography and intravascular ultrasound studies. J Cardiol 2003; 42: 13-22.
141. Miyazawa N, Umemura K, Kondo K, Nakashima M. Effects of pemirolast and tranilast on intimal thickening after arterial injury in the rat. J Cardiovasc Pharmacol 1997; 30: 157-62.
142. Jin D, Takai S, Shiota N, Miyazaki M. Tranilast, an anti-allergic drug, possesses antagonistic potency to angiotensin II. Eur J Pharmacol 1998; 361: 199-205.